Clinical Trial

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

Bonerge is betting that cellular recovery is the key to mitigating the high cost of night shift work. Its real-world trial could redefine human capital investment.

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

A San Diego biotech is advancing a device to clean the blood of disease-fueling particles. With early promise in cancer and a new path in Long COVID, can it navigate the financial realities of innovation?

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

Biomea Fusion's new trial combines its drug icovamenib with semaglutide, aiming not just for weight loss, but to solve a major side effect: muscle loss.

After securing a $114M financing deal, Pyxis Oncology has extended its runway into 2027, putting all focus on upcoming MICVO data for head and neck cancer.

With key FDA backing and promising clinical data, Allogene Therapeutics is advancing a vision where complex cell therapies are not just for major medical centers.

Atea's promising Hep C drug offers a shorter, simpler regimen for complex patients, but faces a tough market. Meanwhile, the firm tackles a neglected virus.

A new study shows 98% success for Mendaera's handheld robot. Beyond the launch, can this device truly bridge the gap in specialized medical skills?

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

A biotech's new funding offers a glimmer of hope for a novel cancer therapy, but a look at the books reveals a desperate race against time and capital.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?

Kodiak Sciences launches a pivotal trial for a new drug aiming to best current treatments for diabetic eye disease. Is this the future of vision care?

A novel dual-action antibody shows remarkable durability in Phase 2 trials, offering a potential six-month dosing schedule for millions with chronic sinusitis.

For millions with treatment-resistant depression, hope is scarce. A Toronto company is pioneering a non-invasive ultrasound therapy that could change everything.

With promising data for its lead cancer drug and a fortified financial runway, C4 Therapeutics is executing a tangible plan to fight a relentless disease.

With 92% response rates in a deadly cancer and $1B in the bank, Tango Therapeutics is not just developing a drug—it's building a new industrial model for precision oncology.

With a strong cash runway, Nkarta pushes its off-the-shelf NK cell therapy into community clinics, setting the stage for a pivotal data reveal in 2026.